Abstract: The present invention relates to the delivery of sedative-hypnotics through an inhalation route. Specifically, it relates to aerosols containing sedative-hypnotics that are used in inhalation therapy. In a method aspect of the present invention, a sedative-hypnotic drug is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of a sedative-hypnotic, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% sedative-hypnotic drug degradation products. In a kit aspect of the present invention, a kit for delivering a sedative-hypnotic through an inhalation route is provided which comprises: a) a thin layer of a sedative-hypnotic drug and b) a device for dispensing said thin layer a sedative-hypnotic drug as a condensation aerosol.

Abstract: The present invention relates to the delivery of antiparkinsons drugs through an inhalation route. In a method aspect of the present invention, an antiparkinsons drug is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of an antiparkinsons drug on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering an antiparkinsons drug through an inhalation route is provided which comprises: a) a thin coating of a an antiparkinsons drug composition; and, b) a device for dispending said thin coating as a condensation aerosol.

Abstract: A new metered unit dose comprising 40 ?g or less of budesonide is disclosed as well as a formulation thereof and the use thereof for the treatment of conditions in the nose.

Abstract: A method for the detection of fibrin in a source, in particular the in vivo detection of a fibrin in a patient, the method comprising supplying to the source or patient an amount of a detectable reagent comprising a plurality of discrete particles, each of the particles comprising a plurality of layers of carbon and being capable of binding to fibrin; and detecting the presence of the particles in the source. The particles may also comprise a detectable marker encased in said plurality of layers of carbon, the presence of said marker being capable of detection in said source.

Abstract: A process for preparing 3-hydroxyalkanals having 3 to 12 carbon atoms by hydration of 2-alkenals with homogeneous catalysis, by using as catalyst a compound corresponding to the formula ##STR1## wherein: z denotes H, C.sub.1 - to C.sub.6 -alkyl, --CH.sub.2 --CH(CH.sub.3) --Y' or --(CH.sub.2).sub.o --Y'R denotes H, C.sub.1 - to C.sub.6 -alkyl, benzyl, phenyl, .omega.-hydroxy --C.sub.1 - to C.sub.6 -alkyl, --CH.sub.2 --CH(CH.sub.3)--Y' or --(CH.sub.2).sub.o --Y'Y and Y' are identical or different and denote --COOH, --P(O) (OH).sub.2, --OH, pyridyl, or --P(O) (CH.sub.2 OH)OH, wherein the acid functional group may be present partly in the form of its alkali metal salt, alkaline-earth salt or ammonium saltn denotes 1, 2, 3, 4, 5 or 6 where Y is --COOH, --P(O) (OH).sub.2, pyridyl or --P(O) (CH.sub.2 OH) OH; 2 or 3 where Y is --OHo denotes 1, 2, 3, 4, 5 or 6 where Y' is --COOH, --P(O) (OH).sub.2, pyridyl or --P(O) (CH.sub.2 OH)OH; 0, 2 or 3 where Y' is --OH.